Rapid test for glycated albumin in blood

a glycated albumin and blood technology, applied in the field of glycated albumin rapid test in blood, can solve the problems of increased risk of vascular disease, retinopathy, neuropathy, hypertension, etc., and achieve the effect of accurate assessment of the overall effectiveness of glycemic control

Inactive Publication Date: 2007-01-18
EPINEX DIAGNOSTICS
View PDF15 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] Frequent monitoring of the individuals glycated albumin would provide an accurate assessment of overall effectiveness of gly

Problems solved by technology

Uncontrolled hyperglycemia is associated with increased risk of vascular disease including, nephropathy, neuropathy, retinopathy, hypertension, and dea

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rapid test for glycated albumin in blood
  • Rapid test for glycated albumin in blood
  • Rapid test for glycated albumin in blood

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] This invention describes a procedure for measuring the percent of glycated albumin compared to total albumin in the patient's blood. The patient's blood sample is placed in a test cassette that contains reagents to perform the test. The test cassette is then inserted into a measuring instrument that reads, calculates, stores and reports the result.

[0017] Principle: The Rapid Assay for glycated albumin utilizes antibodies to glycated albumin and antibodies to total albumin.

Components for Lateral Flow Devices:

[0018] The test strip for measuring glycated albumin is shown in FIGS. 1. It consists of a cellulose nitrate membrane (1) or similar membrane support. There is a sample application pad (2) that serves to remove particulate material and allow the fluid component to flow through. Distal to the sample application pad there is band of anti-albumin antibody labeled with an indicator agent (3). Further along the membrane there is a band of anti-glycated albumin antibody (4) ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention describes a rapid assay for measuring the ratio of glycated albumin to total albumin in blood. Patients with diabetes have elevated levels of glucose in their blood that can react with plasma albumin to form glycated albumin. The amount of glycated albumin formed is directly correlated with the level of plasma glucose that the albumin has been exposed to over a period of time. The ratio of glycated albumin to total albumin in blood will provide an indication of the average amount of protein glycation that occurred over the preceding 2-3 week period. The test is performed using a disposable strip or cassette that contains the testing reagents and the results are measured in a measuring instrument that automatically reads; calculates and displays the final result: The results of tests performed over a period of time are stored in the instrument's memory presented in a numerical or graphical format so that the individual's glycated albumin level can be monitored over time.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The present application is a non provisional application claiming priority to U.S. Provisional patent application Ser. No. 60 / 699,595 entitled RAPID TEST FOR GLYCATED ALBUMIN IN BLOOD, filed Jul. 18, 2005.FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] None BACKGROUND OF THE INVENTION [0003] Diabetes mellitus or diabetes is a disease characterized by elevated levels of plasma glucose. Uncontrolled hyperglycemia is associated with increased risk of vascular disease including, nephropathy, neuropathy, retinopathy, hypertension, and death. There are two major forms of diabetes. Type 1 diabetes (or insulin dependent diabetes) and Type 2 diabetes (or noninsulin dependent diabetes). The American Diabetes Association has estimated that approximately 6% of the world population has diabetes. [0004] The goal of diabetic therapy is to maintain a normal level of glucose in the blood. The American Diabetic Association has recommended that diabeti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/558
CPCG01N33/54386G01N33/6893G01N33/558G01N2333/76G01N33/54388
Inventor SMITH, HENRY JOHN
Owner EPINEX DIAGNOSTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap